The patent grant is a modest positive for IP positioning but provides no clinical data, revenue, or near-term catalyst. With a $2M market cap and no disclosed financials, the stock remains highly speculative. Monitor for clinical trial updates or financing events as the next material catalysts.
Price Chart
Executive Summary
Clearmind Medicine announced the grant of a new U.S. patent (No. 12,357,590) titled 'BINGE BEHAVIOR REGULATORS' covering its MEAI molecule and related 2-aminoindan derivatives for regulating binge behaviors. The patent strengthens the company's IP portfolio, which now includes 19 patent families and 32 granted patents, but provides no clinical data, revenue, or near-term commercialization catalyst.
Key Facts
- Granted U.S. Patent No. 12,357,590 titled 'BINGE BEHAVIOR REGULATORS' by USPTO
- Patent covers MEAI (5-methoxy-2-aminoindane) molecule and related 2-aminoindan derivatives for regulating binge behaviors
- Company's IP portfolio now consists of 19 patent families including 32 granted patents
- Company is a clinical-stage biotech with no disclosed revenue or near-term commercialization catalyst
- Market cap is approximately $2M
Financial Impact
No financial figures disclosed in the filing. Patent grant is an IP portfolio expansion with no immediate revenue or cost impact.
Risk Factors
- No disclosed revenue or near-term commercialization path
- Clinical-stage biotech with no approved products
- Extremely small market cap ($2M) with high volatility and low liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-072864 |
| Document: ea029625402ex99-1.htm | 0001213900-26-072864 |
| Document: 0001213900-26-072864-index-headers.html | 0001213900-26-072864 |
| Document: 0001213900-26-072864-index.html | 0001213900-26-072864 |
| Document: 0001213900-26-072864.txt | 0001213900-26-072864 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers